Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-01-03
2004-11-09
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S262100, C514S365000, C514S562000, C514S706000
Reexamination Certificate
active
06815434
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to methods and compositions for treating and preventing hearing loss.
BACKGROUND OF THE INVENTION
A major cause of acquired hearing loss is loud noise. Exposure to harmful noise levels is common in the workplace. The National Institute for Occupational Safety and Health estimates that about 30 million workers in the United States encounter hazardous levels of noise. (Franks et al. (1996)
Preventing Occupational Hearing Loss—A Practical Guide
, DHHA (NIOSH) Publication No. 96-110, p.1). These levels are encountered in, for example, construction, mining, agriculture, manufacturing and utilities, transportation, and in the military. The incidence of noise associated hearing loss continues to increase in spite of efforts to regulate job related noise exposure, and to improve the use of hearing protective devices such as ear muffs and ear plugs.
Another cause of hearing loss is exposure to ototoxic drugs such as cisplatin and aminoglycoside antibiotics. Accordingly, there is a need for methods and compositions to prevent or treat hearing loss.
SUMMARY OF THE INVENTION
In one aspect the present invention provides methods for ameliorating hearing loss, the methods each comprising the step of administering to a subject an amount of an otoprotectant composition that is effective to ameliorate hearing loss. The otoprotective composition includes at least one of the otoprotectants disclosed herein. In some embodiments, the otoprotective composition comprises a pharmaceutically effective amount of at least one glutathione peroxidase mimic (e.g., a composition comprising ebselen). In some embodiments, the otoprotective composition comprises a pharmaceutically effective amount of (a) at least one glutathione peroxidase mimic and (b) at least one xanthine oxidase inhibitor (e.g., a composition comprising ebselen and allopurinol). In some embodiments, the otoprotective composition comprises a pharmaceutically effective amount of (a) at least one glutathione peroxidase mimic and (b) at least one glutathione or glutathione precursor (e.g., a composition comprising ebselen and N-acetyl-cysteine). In some embodiments, the otoprotective composition comprises a pharmaceutically effective amount of (a) at least one xanthine oxidase inhibitor and (b) at least one glutathione or glutathione precursor (e.g., a composition comprising allopurinol and N-acetyl-cysteine). In some embodiments, the otoprotective composition comprises a pharmaceutically effective amount of (a) at least one glutathione peroxidase mimic, (b) at least one xanthine oxidase inhibitor, and (c) at least one glutathione or glutathione precursor (e.g., a composition comprising ebselen, allopurinol, and N-acetyl-cysteine).
Another aspect of the present invention provides otoprotective compositions useful for ameliorating hearing loss. The otoprotective compositions include at least one of the otoprotectants disclosed herein. In some embodiments, the otoprotective compositions comprise at least one glutathione peroxidase mimic. In some embodiments, the otoprotective compositions comprise at least one glutathione peroxidase mimic and at least one xanthine oxidase inhibitor. In some embodiments, the otoprotective compositions comprise at least one glutathione peroxidase mimic and at least one glutathione or glutathione precursor. In some embodiments, the otoprotective compositions comprise at least one xanthine oxidase inhibitor and at least one glutathione or glutathione precursor. In some embodiments, the otoprotective compositions comprise at least one glutathione peroxidase mimic, at least one xanthine oxidase inhibitor, and at least one glutathione or glutathione precursor.
REFERENCES:
patent: 6177434 (2001-01-01), Kopke et al.
Ren et al. (Archives of Biochemistry and Biophysics, (Mar. 15, 2001) 387 (2), 250-256).*
Usui et al. (Hypertension, (Oct. 1999) 34 (4 Pt 1), 546-51).*
Rybak et al. (Annals of the New York Academy of Sciences (1999), 884 (Ototoxicity) (abstract sent).*
Song et al. (Hearing Research (1996), 94(1/2), 87-93) (abstract sent).*
Dehne et al. (Hearing Research (2000), 143 (1-2), 162-170) 9abstract sent).*
Cotgreave, I.A., and P. Moldéus, “Lung Protection by Thiol-Containing Antioxidants,”Bull. Eur. Physiopathol. Respir. 23:275-277, 1987.
Cotgreave, I.A., et al., “The Anti-Inflammatory Activity of Ebselen But Not Thiols in Experimental Alveolitis and Bronchiolitis,”Agents and Actions24(3-4):313-319, 1988.
Ferrer, J.V., et al., “Allopurinol and N-Acetylcysteine Avoid 60% of Intestinal Necrosis in an Ischemia-Reperfusion Experimental Model,”Transplantation Proceedings30:2672, 1988.
Gustafson, D.L., and C.A. Pritsos, “Inhibition of Mitomycin C's Aerobic Toxicity by the Seleno-Organic Antioxidant PZ-51,”Cancer Chemother. Pharmacol.28(3):228-230, 1991.
McFadden, S.L., et al., “M40403, a Superoxide Dismutase Mimetic, Protects Copchlear Hair Cells From Gentamicin But Not Cisplatin Toxicity,”Toxicology and Applied Pharmacology186:46-54, 2003.
Pritsos, C.A, et al., “PZ-51 (Ebselem) In Vivo protection Against Adriamycin-Induced Mouse Cardiac and Hepatic Lipid Peroxidation and and Toxicity,”Biochemical Pharmacology44(4):839-841, 1992.
Rybak, L.P., et al., “Effect of Protective Agents Against Cisplatin Ototxicity,”The American Journal of Otology21(4):513-520, 2000.
Seidman, M.D., et al., “The Protective Effects of Allopurino and Superoxide Dismutase-Polyethylene Glycol on Ischemic and Reperfusion-Induced Cochlear Damage,Otolaryngology—Head and Neck Surgery,” 105(3):457-463, Sep. 1991.
Vermeulen, N.P.E., et al., “Toxicity of Fotemustine in Rat Hepatocytes and Mechanism-Based Protection Against It,”Chemico-Biological Interactions110:139-158, 1998.
Kil Jonathan
Lynch Eric D.
Christensen O'Connor Johnson & Kindness PLLC
Henry Michael C.
Sound Pharmaceuticals Incorporated
Wilson James O.
LandOfFree
Methods for treating hearing loss does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating hearing loss, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating hearing loss will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3317159